AIM

AIM is a pre-commercial biotech whose only revenue is an $88K Ampligen 'Cost Recovery Program' — down 48% YoY and immaterial against a $14M net loss. The 25.9x P/S is a nonsense multiple applied to a rounding-error top line; there is no business to value here, only a drug candidate and a cash runway. FY2025's 'improved' net loss is a mirage: the $3.4M narrower loss was driven almost entirely by non-recurring items MD&A explicitly flags as non-recurring — $3.0M of forgiven legal fees booked as other income and prior-year litigation-related G&A that simply didn't repeat — while true operating burn remains catastrophic.

The balance sheet is broken. Stockholders' equity is NEGATIVE $9.78M (down 640% YoY), total liabilities jumped 57% to $15.6M, and the current portion of debt rose to $3.55M. Against that, cash is just $2.98M while operating cash burn ran $11.0M in FY2025 — roughly three months of runway. The Risk Factors lead with 'We will require additional financing which may not be available,' and the company confirms its Atlas $15M equity line lapsed in February 2025, forcing it back to the market via the July 2025 public offering (2M shares at $4.00 with two tranches of warrants).